The stock market has been on a tear over the past two years. With the major indexes hitting multi-year highs recently, the value pickings are slim. But one highlights five stocks that still have attractive prices in this rising market.
Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and they are in far less danger from generic competition. Here are the big winners so far this year.
As the world hopes for an HIV vaccine following recent positive developments, a new study in South Africa shows that a vaginal gel made using Gilead Sciences' AIDS drug Viread cut HIV infections in women by as much as 50%.
If the health care bills in Congress become law, the biotech sector may become one of the biggest beneficiaries. Here are six stocks and mutual funds that stand to gain the most from the changes.
